Quark gets specific

Why Quark Venture backed antibiotics company Abac

Abac Therapeutics S.A.’s targeted approach to antibiotic development led Quark Venture to join the company’s €16 million ($19.6 million) series A round, which will enable it to bring its lead program into the

Read the full 336 word article

User Sign In